These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8978757)

  • 1. L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro.
    Mytilineou C; Radcliffe PM; Olanow CW
    J Neurochem; 1997 Jan; 68(1):434-6. PubMed ID: 8978757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro.
    Mytilineou C; Radcliffe P; Leonardi EK; Werner P; Olanow CW
    J Neurochem; 1997 Jan; 68(1):33-9. PubMed ID: 8978707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion.
    Mytilineou C; Leonardi EK; Radcliffe P; Heinonen EH; Han SK; Werner P; Cohen G; Olanow CW
    J Pharmacol Exp Ther; 1998 Feb; 284(2):700-6. PubMed ID: 9454817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-deprenyl fails to protect mesencephalic dopamine neurons and PC12 cells from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion.
    Vaglini F; Pardini C; Cavalletti M; Maggio R; Corsini GU
    Brain Res; 1996 Nov; 741(1-2):68-74. PubMed ID: 9001706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deprenyl rescues dopaminergic neurons in organotypic slice cultures of neonatal rat mesencephalon from N-methyl-D-aspartate toxicity.
    Shimazu S; Katsuki H; Akaike A
    Eur J Pharmacol; 1999 Jul; 377(1):29-34. PubMed ID: 10448922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor.
    Finberg JP; Takeshima T; Johnston JM; Commissiong JW
    Neuroreport; 1998 Mar; 9(4):703-7. PubMed ID: 9559942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The multiple actions of selegiline.
    Ebadi M; Sharma S; Shavali S; Sangchot P; Brekke L
    Proc West Pharmacol Soc; 2002; 45():39-41. PubMed ID: 12434521
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of MAO-B inhibitors on MPP+ toxicity in Vivo.
    Wu RM; Chen RC; Chiueh CC
    Ann N Y Acad Sci; 2000; 899():255-61. PubMed ID: 10863544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans.
    Heinonen EH; Anttila MI; Karnani HL; Nyman LM; Vuorinen JA; Pyykkö KA; Lammintausta RA
    J Clin Pharmacol; 1997 Jul; 37(7):602-9. PubMed ID: 9243353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.
    Knoll J
    Pharmacol Toxicol; 1998 Feb; 82(2):57-66. PubMed ID: 9498233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effects of selegiline and desmethylselegiline against N-methyl-D-aspartate-induced rat retinal damage.
    Takahata K; Katsuki H; Kobayashi Y; Muraoka S; Yoneda F; Kume T; Kashii S; Honda Y; Akaike A
    Eur J Pharmacol; 2003 Jan; 458(1-2):81-9. PubMed ID: 12498910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selegiline protects dopaminergic neurons in culture from toxic factor(s) present in the cerebrospinal fluid of patients with Parkinson's disease.
    Hao R; Ebadi M; Pfeiffer RF
    Neurosci Lett; 1995 Nov; 200(2):77-80. PubMed ID: 8614567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
    Magyar K; Szende B
    Neurotoxicology; 2004 Jan; 25(1-2):233-42. PubMed ID: 14697898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective actions of selegiline.
    Ebadi M; Sharma S; Shavali S; El Refaey H
    J Neurosci Res; 2002 Feb; 67(3):285-9. PubMed ID: 11813232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture.
    Goggi J; Theofilopoulos S; Riaz SS; Jauniaux E; Stern GM; Bradford HF
    Neuroreport; 2000 Dec; 11(18):3937-41. PubMed ID: 11192605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
    Muralikrishnan D; Samantaray S; Mohanakumar KP
    Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease.
    Chiu WH; Carlsson T; Depboylu C; Höglinger GU; Oertel WH; Ries V
    Neuropharmacology; 2014 Apr; 79():212-21. PubMed ID: 24291466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons.
    Engberg G; Elebring T; Nissbrandt H
    J Pharmacol Exp Ther; 1991 Nov; 259(2):841-7. PubMed ID: 1658311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-deprenyl (selegiline) decreases excitatory synaptic transmission in the rat hippocampus via a dopaminergic mechanism.
    Hsu KS; Huang CC; Su MT; Tsai JJ
    J Pharmacol Exp Ther; 1996 Nov; 279(2):740-7. PubMed ID: 8930179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.